Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
| Autor: | Sharman, Jeff P *, Brander, Danielle M, Mato, Anthony R, Ghosh, Nilanjan, Schuster, Stephen J, Kambhampati, Suman, Burke, John M, Lansigan, Frederick, Schreeder, Marshall T, Lunin, Scott D, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M, Chandler, Jason C, Kolibaba, Kathryn S, Sportelli, Peter, Miskin, Hari P, Weiss, Michael S, Flinn, Ian W |
|---|---|
| Zdroj: | In The Lancet Haematology April 2021 8(4):e254-e266 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|